The estimated Net Worth of Pritesh Shah is at least $21 Milione dollars as of 7 November 2023. Mr. Shah owns over 382 units of NovoCure Ltd stock worth over $2,145,325 and over the last 6 years he sold NVCR stock worth over $15,283,306. In addition, he makes $3,620,970 as Chief Commercial Officer at NovoCure Ltd.
Pritesh has made over 50 trades of the NovoCure Ltd stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 382 units of NVCR stock worth $4,832 on 7 November 2023.
The largest trade he's ever made was exercising 40,586 units of NovoCure Ltd stock on 1 March 2019 worth over $558,869. On average, Pritesh trades about 7,798 units every 29 days since 2018. As of 7 November 2023 he still owns at least 124,511 units of NovoCure Ltd stock.
You can see the complete history of Mr. Shah stock trades at the bottom of the page.
Pritesh Shah serves as Chief Commercial Officer of the Company. Mr. Shah served as the Company’s Senior Vice President, Americas since March 2016, as General Manager, US from January 2014 to March 2016 and he has held other sales and marketing roles with the Company since 2012. Prior to joining Novocure, Mr. Shah had extensive experiences in leading Oncology commercial and medical affairs functions at Roche, Genentech, Bristol-Myers Squibb, OSI Oncology and AVEO Oncology. Mr. Shah holds a Doctor of Pharmacy from the University of Maryland and a master’s degree in Strategic Communication and Leadership from Seton Hall University.
As the Chief Commercial Officer of NovoCure Ltd, the total compensation of Pritesh Shah at NovoCure Ltd is $3,620,970. There are 4 executives at NovoCure Ltd getting paid more, with William Doyle having the highest compensation of $8,286,100.
Pritesh Shah is 42, he's been the Chief Commercial Officer of NovoCure Ltd since 2018. There are 22 older and 1 younger executives at NovoCure Ltd. The oldest executive at NovoCure Ltd is Prof. Yoram Palti, 83, who is the Founder & CTO.
Pritesh's mailing address filed with the SEC is C/O NOVOCURE INC., 1550 LIBERTY RIDGE DRIVE, SUITE 115, WAYNE, PA, 19087.
Over the last 9 years, insiders at NovoCure Ltd have traded over $237,132,855 worth of NovoCure Ltd stock and bought 164,174 units worth $2,198,429 . The most active insiders traders include Asaf Danziger, William Fwfd Ventures Fund ... e Michael J. Ambrogi. On average, NovoCure Ltd executives and independent directors trade stock every 7 days with the average trade being worth of $853,350. The most recent stock trade was executed by Ashley Cordova on 2 August 2024, trading 688 units of NVCR stock currently worth $13,856.
we are a commercial-stage oncology company developing a novel, proprietary therapy called tumor treating fields, or ttfields, for the treatment of solid tumor cancers. we count on the contributions of our talented team members who are committed to improving the lives of cancer patients. here at novocure, cancer patients and their families are – and have always been – at the core of our mission. we expect our colleagues to excel, and in return, we invest in their professional growth and personal well-being. we seek high performers who thrive in fast-paced environments and are inspired by making a difference in cancer care. we offer employment opportunities in the u.s., europe and asia.
NovoCure Ltd executives and other stock owners filed with the SEC include: